We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Top Research Reports for Johnson & Johnson, Nike & BP
Read MoreHide Full Article
Friday, August 24, 2018
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ - Free Report) , Nike (NKE - Free Report) and BP (BP - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Johnson & Johnson’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry in the last three months, gaining +11.2% vs. +10.5%. J&J’s sales growth has accelerated since second half of 2017 backed by higher sales in the Pharmaceutical unit and improving performance in Medical Devices unit.
J&J has already raised its full-year organic sales growth expectations twice this year. Though quite a few key products in J&J’s portfolio, like Remicade and Concerta, are facing generic competition, the Zacks analyst believes that new products across segments, successful label expansion of cancer drugs like Imbruvica and Darzalex and contributions from recent acquisitions will continue to drive top-line growth.
J&J also enjoys a robust multi-year pipeline of new drugs and line extensions. Meanwhile, share buybacks and restructuring initiatives should provide bottom-line support.
Shares of Nike have gained +14.8% in the last three months, outperforming the Zacks Shoes and Retail Apparel industry, which gained 12.8% over the same period. The company has delivered positive earnings for over three years now, with fourth-quarter fiscal 2018 marking the 24th straight quarter of earnings beat.
Moreover, sales topped estimates for the fifth straight quarter. Strong progress on Consumer Direct Offense through innovation and focus on direct-to-customer are the key drivers.
Additionally, continued growth at international and Nike Direct businesses, as well as the return of the North America business to growth in the fiscal fourth quarter, aided results. Driven by these positives, the company raised its revenue guidance for fiscal 2019.
BP’s shares have outperformed the Zacks International Integrated Oil industry over the past year (24.4% vs. 13.6%). The integrated energy company has been gaining on the back of a strong portfolio of upstream projects. Since 2016, BP has placed 16 key upstream projects online, including Atoll Phase 1, Shah Deniz 2 and Taas-Yuryakh oil expansion in Russia.
Such developments continue assisting the British energy giant to boost production by 900 thousand barrel of oil equivalent per day (MBOE/D) by 2021. Moreover, the company has a strong commitment in returning cash back to the shareholders through share buybacks and dividend payments.
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Top Research Reports for Johnson & Johnson, Nike & BP
Friday, August 24, 2018
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ - Free Report) , Nike (NKE - Free Report) and BP (BP - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Johnson & Johnson’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry in the last three months, gaining +11.2% vs. +10.5%. J&J’s sales growth has accelerated since second half of 2017 backed by higher sales in the Pharmaceutical unit and improving performance in Medical Devices unit.
J&J has already raised its full-year organic sales growth expectations twice this year. Though quite a few key products in J&J’s portfolio, like Remicade and Concerta, are facing generic competition, the Zacks analyst believes that new products across segments, successful label expansion of cancer drugs like Imbruvica and Darzalex and contributions from recent acquisitions will continue to drive top-line growth.
J&J also enjoys a robust multi-year pipeline of new drugs and line extensions. Meanwhile, share buybacks and restructuring initiatives should provide bottom-line support.
(You can read the full research report on Johnson & Johnson here >>>).
Shares of Nike have gained +14.8% in the last three months, outperforming the Zacks Shoes and Retail Apparel industry, which gained 12.8% over the same period. The company has delivered positive earnings for over three years now, with fourth-quarter fiscal 2018 marking the 24th straight quarter of earnings beat.
Moreover, sales topped estimates for the fifth straight quarter. Strong progress on Consumer Direct Offense through innovation and focus on direct-to-customer are the key drivers.
Additionally, continued growth at international and Nike Direct businesses, as well as the return of the North America business to growth in the fiscal fourth quarter, aided results. Driven by these positives, the company raised its revenue guidance for fiscal 2019.
(You can read the full research report on NIKE here >>>).
BP’s shares have outperformed the Zacks International Integrated Oil industry over the past year (24.4% vs. 13.6%). The integrated energy company has been gaining on the back of a strong portfolio of upstream projects. Since 2016, BP has placed 16 key upstream projects online, including Atoll Phase 1, Shah Deniz 2 and Taas-Yuryakh oil expansion in Russia.
Such developments continue assisting the British energy giant to boost production by 900 thousand barrel of oil equivalent per day (MBOE/D) by 2021. Moreover, the company has a strong commitment in returning cash back to the shareholders through share buybacks and dividend payments.
(You can read the full research report on BP here >>>).
Other noteworthy reports we are featuring today include eBay (EBAY - Free Report) , Global Payments (GPN - Free Report) and BCE (BCE - Free Report) .
Mark Vickery
Senior Editor
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>